Spruce Biosciences (SPRB) Fireside Chat - SPRUCE BIOSCIENCES INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures provided as the company is pre-revenue (development stage); no debt or deferred revenue metrics disclosed.
• Manufacturing costs managed via completion of PPQ (Process Performance Qualification) batches and drug substance/product filling at Samsung Biologics.
• Patient identification efforts show early "meaningful demand" exceeding Year 1 projected treatment volumes based on Expanded Access Program (EAP) sign-ups.

Guidance and Future Outlook:

• BLA Submission: Confirmed guidance for Biologics License Application (BLA) submission in Q4 of the current year.
• Commercial Launch: Anticipates a commercial launch in the upcoming year.
• Market Growth: Expects new patient identification to increase following Ultragenyx's MPS3A approval and potential newborn screening initiatives.
• Long-term Goals: Aims to extend patient lifespan and preserve neurocognitive function, allowing patients to achieve milestones (e.g., speech, schooling) previously unheard of in the disease context.

Business Segments and Product Lines:

• Core Asset: TA-ERT (enzyme replacement therapy) for MPS3B (Sanfilippo Syndrome Type B), a neuronopathic disorder causing pediatric dementia.
• Delivery Method: Administered via an intracerebroventricular (ICV) device into the CSF, with efficacy extending to peripheral clearance of heparin sulfate in the liver and spleen.
• Clinical Data: Submission includes robust effect sizes on Heparin Sulfate (surrogate endpoint), cognition (BSID), adaptive behavior, motor skills, MRI, and communication.
• Supply Chain: Completed manufacturing of Drug Substance (DS) and Drug Product (DP) under PPQ framework; PPQ-2 filling scheduled for later in the quarter.

Market and Competitive Landscape:

• Target Population: Estimated ~450 MPS3B patients in the U.S.; ~20 new diagnoses annually.
• Pricing Strategy: Fixed dosing (non-weight-based); management targets an annual price point between $1 million and $2 million per patient.
• Competitive Context: Comparables include weight-based therapies reaching up to $2.5–$2.8M/year; positioning aims to compete with global pricing pressures and Multi-Function Negotiation (MFN) requirements.
• Patient Access: Strong engagement with CURE San Felipe and National MPS Society, who have funded EAP product distribution.

Risks and Challenges:

• Regulatory Approval: Ultimate approval pathway (Accelerated vs. Full) remains FDA-dependent; potential need for a patient registry or confirmatory study if accelerated approval is granted.
• Diagnosis Lag: Current lack of ICD-10 specificity for MPS3B leads to diagnostic imprecision; diagnosis often occurs ~4 years old despite symptoms appearing at ~2.5 years.
• Manufacturing Disruption: Samsung Biologics labor strikes are possible but deemed low risk due to historical resolution and available non-unionized workforce capacity.
• Payer Negotiation: Potential pricing sensitivity and competition in non-U.S. markets requiring strategic distribution partnerships.

Management Commentary and Tone:

• Tone: Highly confident and optimistic regarding the robustness of the clinical package, FDA alignment on endpoints, and the potential for a full approval similar to the recent MPS3A gene therapy.
• CEO Focus: Javier Schwartberg emphasized the "profound effect size" of the data, the company's early diagnosis acceleration strategy, and the "good momentum" in the patient community.
• Strategic Clarity: Management clearly distinguished their use of in-house natural history data versus external controls and highlighted the fixed-dosing advantage over weight-based competitors.

Analyst Questions and Answers:

• Q: Impact of Samsung Biologics strikes? A: Negligible; strikes historically resolve quickly, and the manufacturer has excess capacity to cover disruptions.
• Q: Comparison to Ultragenyx (MPS3A)? A: Spruce's package includes BSID raw scores and heparin sulfate data similar to Ultragenyx, but utilizes a robust in-house natural history study for modeling to adjust baseline imbalances.
• Q: Full vs. Accelerated Approval? A: Full approval would eliminate the need for a post-marketing confirmatory study (replacing it likely with a registry), allowing broader commercial messaging; however, the priority review voucher pathway remains unchanged.
• Q: Patient Eligibility/Age? A: No upper age limit; treatment decisions rest with physicians/families, though management expects high acceptance even in advanced stages to halt progression.
• Q: Pricing expectations? A: Proposed range of $1M–$2M annually per patient based on fixed dosing and global market considerations.

Other Key Points:

• Mechanism of Action: The drug targets the removal of accumulating heparin sulfate substrates in neurons, aiming to reverse neuroinflammation and neurodegeneration.
• Expanded Access: Significant interest in the EAP program with families actively signing up via mps3bstudy.com.
• Global Opportunity: While U.S. market is ~450 patients, the global patient population is estimated to be larger.
• Diagnostic Paradox: Early diagnosis is critical; untreated patients typically plateau around age 4 before rapid decline into loss of motor skills, speech, and eventual death in their late teens.